Kevin X Liu1, Nayan Lamba2, William L Hwang3, Andrzej Niemierko4, Steven G DuBois2,5, Daphne A Haas-Kogan2,6. 1. Department of Medicine, University of California San Diego School of Medicine, La Jolla, California. 2. Harvard Medical School, Boston, Massachusetts. 3. Harvard Radiation Oncology Program, Harvard Medical School, Boston, Massachusetts. 4. Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. 5. Department of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts. 6. Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham & Women's Hospital, Boston Children's Hospital, Boston, Massachusetts.
Abstract
BACKGROUND: Up to one-third of patients with localized Ewing sarcoma (ES) develop recurrent disease, but current biomarkers do not accurately identify this high-risk group. Therefore, the objective of this study was to determine the utility of mutational burden in predicting outcomes in patients with localized ES. METHODS: Clinical and genomic data from 99 patients with ES, of whom 63 had localized disease at diagnosis, were obtained from the cBioPortal for Cancer Genomics. Genomic data included the type and number of somatic mutations using cBioPortal mutation calling. Primary endpoints were overall survival (OS) and the time to progression (TTP). RESULTS: Patients had a median number of 11 somatic mutations. Patients were stratified according to whether they had a lower or higher mutational burden if they had ≤11 or >11 mutations, respectively. Higher mutational burden was significantly associated with inferior OS and TTP, a finding that was confirmed by univariate and multivariable analyses. In patients who had localized disease at diagnosis, higher mutational burden was the only variable significantly associated with inferior OS and TTP. The presence of a mutation in either stromal antigen 2 (STAG2) or tumor protein 53 (TP53), both of which were correlated previously with shorter OS in patients with ES, were significantly associated with higher mutational burden. Upon stratifying patients who had localized disease based on a standard panel of cancer genes, higher risk stratification was correlated significantly with inferior TTP and trended toward significance with inferior OS. CONCLUSIONS: Patients who have localized ES and a higher mutational burden have inferior OS and TTP compared with those who have lower mutation burden. The current findings suggest that the somatic mutation burden can be used to better risk stratify these patients and to guide clinical decision making.
BACKGROUND: Up to one-third of patients with localized Ewing sarcoma (ES) develop recurrent disease, but current biomarkers do not accurately identify this high-risk group. Therefore, the objective of this study was to determine the utility of mutational burden in predicting outcomes in patients with localized ES. METHODS: Clinical and genomic data from 99 patients with ES, of whom 63 had localized disease at diagnosis, were obtained from the cBioPortal for Cancer Genomics. Genomic data included the type and number of somatic mutations using cBioPortal mutation calling. Primary endpoints were overall survival (OS) and the time to progression (TTP). RESULTS:Patients had a median number of 11 somatic mutations. Patients were stratified according to whether they had a lower or higher mutational burden if they had ≤11 or >11 mutations, respectively. Higher mutational burden was significantly associated with inferior OS and TTP, a finding that was confirmed by univariate and multivariable analyses. In patients who had localized disease at diagnosis, higher mutational burden was the only variable significantly associated with inferior OS and TTP. The presence of a mutation in either stromal antigen 2 (STAG2) or tumor protein 53 (TP53), both of which were correlated previously with shorter OS in patients with ES, were significantly associated with higher mutational burden. Upon stratifying patients who had localized disease based on a standard panel of cancer genes, higher risk stratification was correlated significantly with inferior TTP and trended toward significance with inferior OS. CONCLUSIONS:Patients who have localized ES and a higher mutational burden have inferior OS and TTP compared with those who have lower mutation burden. The current findings suggest that the somatic mutation burden can be used to better risk stratify these patients and to guide clinical decision making.
Authors: Yusuke Tsuda; Brendan C Dickson; David Swanson; Yun-Shao Sung; Lei Zhang; Paul Meyers; John H Healey; Cristina R Antonescu Journal: Genes Chromosomes Cancer Date: 2019-12-03 Impact factor: 5.006
Authors: Eric S Schafer; Rachel E Rau; Stacey L Berg; Xiaowei Liu; Charles G Minard; Alexander J R Bishop; J Carolina Romero; M John Hicks; Marvin D Nelson; Stephan Voss; Joel M Reid; Elizabeth Fox; Brenda J Weigel; Susan M Blaney Journal: Pediatr Blood Cancer Date: 2019-11-14 Impact factor: 3.838
Authors: Giuseppina Sannino; Aruna Marchetto; Andreas Ranft; Susanne Jabar; Constanze Zacherl; Rebeca Alba-Rubio; Stefanie Stein; Fabienne S Wehweck; Merve M Kiran; Tilman L B Hölting; Julian Musa; Laura Romero-Pérez; Florencia Cidre-Aranaz; Maximilian M L Knott; Jing Li; Heribert Jürgens; Ana Sastre; Javier Alonso; Willian Da Silveira; Gary Hardiman; Julia S Gerke; Martin F Orth; Wolfgang Hartmann; Thomas Kirchner; Shunya Ohmura; Uta Dirksen; Thomas G P Grünewald Journal: EBioMedicine Date: 2019-08-16 Impact factor: 8.143
Authors: David S Shulman; Sarah B Whittle; Didier Surdez; Kelly M Bailey; Enrique de Álava; Jason T Yustein; Adam Shlien; Masanori Hayashi; Alexander J R Bishop; Brian D Crompton; Steven G DuBois; Neerav Shukla; Patrick J Leavey; Stephen L Lessnick; Heinrich Kovar; Olivier Delattre; Thomas G P Grünewald; Cristina R Antonescu; Ryan D Roberts; Jeffrey A Toretsky; Franck Tirode; Richard Gorlick; Katherine A Janeway; Damon Reed; Elizabeth R Lawlor; Patrick J Grohar Journal: NPJ Precis Oncol Date: 2022-09-17